HUTCHMED (NASDAQ:HCM) Trading Down 4.5% – Should You Sell?

HUTCHMED (China) Limited (NASDAQ:HCM)’s stock price was down 4.5% during mid-day trading on Tuesday . The company traded as low as $15.01 and last traded at $15.10. Approximately 16,653 shares were traded during trading, a decline of 82% from the average daily volume of 90,882 shares. The stock had previously closed at $15.81.

Analyst Ratings Changes

Separately, StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Monday, November 18th.

HUTCHMED Stock Down 4.4 %

The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. The firm has a fifty day moving average of $16.59 and a 200 day moving average of $17.85.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers increased its holdings in HUTCHMED by 8.1% in the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after acquiring an additional 564 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in shares of HUTCHMED by 9.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock valued at $226,000 after purchasing an additional 1,168 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of HUTCHMED in the third quarter worth about $35,000. China Universal Asset Management Co. Ltd. lifted its position in shares of HUTCHMED by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock worth $117,000 after buying an additional 2,321 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock valued at $69,000 after buying an additional 3,057 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.